Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.61 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057527 | 1.00 | MITF (0.74) | MITFMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL24451139 | 0.86 | MAPT (0.72) | MITFMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6511554 | 0.85 | MAPT (0.67) | MITFMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6511560 | 0.85 | MAPT (0.67) | MITFMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL17616161 | 0.78 | MEN1 (1.00) | MITFMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6509381 | 0.74 | MAPT (0.78) | MITFMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6509384 | 0.74 | MAPT (0.78) | MITFMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL480762 | 0.74 | LMNA (0.67) | MITFMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL480760 | 0.74 | LMNA (0.67) | MITFMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL5743189 | 0.69 | POLB (0.50) | MITFMAPTMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504398-B2 | potent and selective antagonists of adenosine receptors; Parkinson's disease, asthma, allergies, inflammation, atherosclerosis, hypertension, gastrointestinal disorders, cell proliferation and autoimmune diseases; sulfonamidation | LABORATORIOS ALMIRALL S.A. (ES) | 2009-03-17 | — | — | US | disclosed |
| US-20050261248-A1 | New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261248-A1 | New-4-pyrrolopyrimidin-6-YL)benzenesulphonamide derivatives | ADORA2B, ADORA2A, ADORA3 | MITF 3728/4885MAPT 4635/4885MEN1 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.